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Original articleMitochondrial dysfunction has divergent, cell
type-dependent effects on insulin actionSheree D. Martin 1, Shona Morrison 1, Nicky Konstantopoulos 1, Sean L. McGee 1,2,*ABSTRACT
The contribution of mitochondrial dysfunction to insulin resistance is a contentious issue in metabolic research. Recent evidence implicates
mitochondrial dysfunction as contributing to multiple forms of insulin resistance. However, some models of mitochondrial dysfunction fail to
induce insulin resistance, suggesting greater complexity describes mitochondrial regulation of insulin action. We report that mitochondrial
dysfunction is not necessary for cellular models of insulin resistance. However, impairment of mitochondrial function is sufﬁcient for insulin
resistance in a cell type-dependent manner, with impaired mitochondrial function inducing insulin resistance in adipocytes, but having no effect,
or insulin sensitising effects in hepatocytes. The mechanism of mitochondrial impairment was important in determining the impact on insulin
action, but was independent of mitochondrial ROS production. These data can account for opposing ﬁndings on this issue and highlight the
complexity of mitochondrial regulation of cell type-speciﬁc insulin action, which is not described by current reductionist paradigms.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Type 2 diabetes (T2D) involves insulin resistance in skeletal muscle,
the liver and adipose tissue [1]. One of the most contentious issues in
metabolic research is the role of mitochondrial dysfunction in the
development of insulin resistance. The term mitochondrial dysfunction
can describe impairments in numerous mitochondrial function indices,
including respiration, ATP production, membrane potential, proton leak
and reactive oxygen species (ROS) production [2]. Impaired mito-
chondrial function has been observed in skeletal muscle [3e6], the
liver [7e9] and adipose tissue [10e12] of T2D patients and animal
models of T2D. Similar impairments have been observed in the skeletal
muscle of insulin resistant offspring of T2D patients [13]. This could
suggest a role for impaired mitochondrial function in the development
of insulin resistance. This is supported by observations of insulin
resistance in humans with mitochondrial DNA mutations that result in
impaired mitochondrial function [14e16]. Mitochondrial dysfunction
has been proposed to induce insulin resistance through ectopic lipid
accumulation secondary to reduced b-oxidation, which impairs insulin
signalling [17,18]. More recently, production of ROS has emerged as a
direct link between mitochondrial dysfunction and insulin resistance
driven by numerous insults such as saturated fatty acids, inﬂammatory
cytokines and glucocorticoids [19,20]. However, numerous animal
models with impaired mitochondrial function have either unchanged or
increased insulin sensitivity [21e23], questioning both the causality of1Metabolic Remodelling Laboratory, Metabolic Research Unit, School of Medicine, Deakin University,
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and/or sufﬁcient for insulin resistance. Further adding to controversy
on this issue, anti-diabetic agents such as the biguanide and thiazo-
lidinedione family of compounds, which enhance insulin action pri-
marily in the liver and adipose tissue respectively, have been reported
to inhibit complex I of the electron transport chain and/or the mito-
chondrial pyruvate carrier (MPC), which impairs mitochondrial function
[24e26]. These counterintuitive ﬁndings have been balanced by evi-
dence that biguanides can prevent ROS production by complex I under
conditions of electron backﬂow from complex II, such as during high fat
feeding [27]. However, given that most of our knowledge regarding the
role of mitochondria in the regulation of insulin action has been
generated from studies of skeletal muscle, coupled with the fact that
the primary tissues of action of these anti-diabetic drugs are not
skeletal muscle, could raise the possibility that there are cell/tissue
type-speciﬁc responses in this relationship that are not yet fully un-
derstood. Indeed, studies of either insulin resistant humans or animal
models of mitochondrial dysfunction have not been able to mecha-
nistically dissect this relationship with any certainty. This is due to
reasons such as the non-physiological nature of gene ablation, the
markedly different mitochondrial respiratory rates and metabolic
function of tissues involved in whole body insulin action, the complexity
in controlling substrate ﬂux to individual insulin-sensitive tissues and
inter-tissue cross-talk in vivo. While these factors are important for the
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tance, they are nonetheless confounding variables when examining the
fundamental link between mitochondrial dysfunction and insulin
action.
The fundamental biology underpinning these paradoxical ﬁndings
describing the relationship between mitochondria and insulin action
is poorly understood. Indeed, the potential importance of speciﬁc
mitochondrial enzyme impairments and the tissue/cell type in which
impairments occur are unknown. Furthermore, it is unknown how
alterations in many of the interdependent indices of mitochondrial
function impact on cellular insulin action. As in vivo studies have
been unable to dissect these mechanisms, fundamental studies in
cellular systems that deﬁne the biological complexity in the rela-
tionship between mitochondrial function and insulin action in mul-
tiple cell types are required before our understanding of the
physiological role of mitochondria in the development of insulin
resistance can advance. Therefore, the aims of this study were to:
1. determine whether mitochondrial dysfunction is necessary and/or
sufﬁcient for cellular insulin resistance; 2. establish whether speciﬁc
mitochondrial enzyme impairment is important for this response in a
cell type-dependent manner; and 3. assess whether ROS production
is a universal link between impaired mitochondrial function and
insulin resistance. We used 3T3L1 adipocytes and FAO hepatoma
cells, as models of adipocytes and hepatocytes, respectively, to
address these aims, assessing glucose uptake and suppression of
glucose production as measures of insulin action. These cell lines
have been used extensively to study insulin action and these cell
types are characterised by impaired mitochondrial function in insulin
resistant states [7,12]. However, few studies have utilised these cell
types to mechanistically examine the role of mitochondria in insulin
action.
2. MATERIALS AND METHODS
2.1. Cell culture
Mouse immortalised 3T3L1 ﬁbroblasts were cultured in 10% CO2 at
37 C in growth media consisting of DMEM (4.5 g/L glucose; Invi-
trogen), 10% heat-inactivated foetal bovine serum (HI-FBS; Thermo
Scientiﬁc) and antibiotics (100 units/mL penicillin and 100 mg/mL
streptomycin; Life Technologies). Cells were induced to differentiate 2
days after reaching conﬂuence (day 0), by supplementing growth
media with 3 nM insulin (Humulin R; Eli Lilly), 0.25 mM dexamethasone
(SigmaeAldrich) and 0.5 mM 1-methyl-3-isobutyl-xanthine (Sigmae
Aldrich). From day 3 until day 7, cells were maintained in growth media
supplemented with 3 nM insulin after which the mature adipocytes
were maintained in growth media. All treatments were for 24 h in
growth media unless stated otherwise. Rat FAO immortalised hepa-
toma hepatocytes [28] were cultured in 5% CO2 at 37 C in growth
media consisting of RPMI 1640 medium (2 g/L glucose; Invitrogen) and
10% foetal bovine serum (FBS; Thermo Scientiﬁc). Assays were car-
ried out when cells were w90% conﬂuent. All treatments of hepa-
tocytes were for 24 h in glucose- and serum-free RPMI 1640 media
supplemented with 2 mM sodium pyruvate, 20 mM sodium L-lactate
and 0.1% BSA (glucose production media; GP media), except where
indicated. For 3T3L1 models of insulin resistance, cells were treated
with 25 mU/mL glucose oxidase (G.O.; SigmaeAldrich), 10 ng/mL
tumour necrosis factor-a (TNFa; Peprotech) or 10 nM chronic insulin.
For chronic insulin treatments, cells were returned to growth media
containing no insulin 2 h before beginning glucose uptake assays or
protein collection. Treatment doses for oligomycin (SigmaeAldrich)
and rotenone (SigmaeAldrich) models of mitochondrial dysfunction as
well as Antimycin A (SigmaeAldrich) and FCCP (Carbonyl cyanide 4-MOLECULAR METABOLISM 3 (2014) 408e418  2014 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.com(triﬂuoromethoxy) phenylhydrazone; SigmaeAldrich) in both 3T3L1
and FAO cells are as stated in Figures 2 and 3, Figures S2 and S3 . The
doses of rosiglitazone and phenformin are stated in Figure 4 and
Figure S4. MnTBAP (Manganese (III) tetrakis (4-benzoic acid) porphyrin
chloride; Enzo Life Sciences) co-treatments were at a dose of 300 mM
and wortmannin (wort; SigmaeAldrich) co-treatments were at a dose
of 100 nM.
2.2. Bioenergetics and respiration analyses
The cellular bioenergetics proﬁle of 3T3L1 adipocytes and FAO he-
patocytes was assessed using the Seahorse XF24 Flux Analyzer
(Seahorse Bioscience). 3T3L1 ﬁbroblasts were seeded into a 24-well
XF24 cell culture microplate (Seahorse Bioscience) and were differ-
entiated to maturity, as described above, at which time the cells were
treated for 24 h. FAO hepatocytes were also seeded into a XF24
microplate at a density of 50,000 cells per well and 4 h later, 24 h
treatments were begun in growth media. Cells were washed and
incubated in 600 ml unbuffered DMEM (containing 25 mM glucose,
1 mM pyruvate and 1 mM glutamate) pH 7.4, at 37 C in a non-CO2
incubator (1 h prior to bioenergetics assessment). Three basal oxygen
consumption rate (OCR) measurements were performed using the
Seahorse analyzer, and measurements were repeated following in-
jection of oligomycin (1 mM), FCCP (1 mM) and Antimycin A (1 mM).
Basal extracellular acidiﬁcation rate (ECAR) was determined from data
collected at basal measurement points. Calculations of respiratory
parameters of mitochondrial function were performed as previously
described [29] and included subtraction non-mitochondrial respiration
from all mitochondrial respiration parameters. Following completion
of the assay cell number was determined using the CyQuant Cell
Proliferation Assay kit (Molecular Probes) according to manufacturer’s
instructions.
2.3. Glucose uptake assay
Mature adipocytes in 24-well plates were treated for 24 h with insults,
mitochondrial inhibitors or anti-diabetic agents, as described above, in
serum-starve media consisting of DMEM (4.5 g/L glucose) supple-
mented with 0.2% fatty acid-free bovine serum albumin (BSA; USB
Corporation). To begin the assay, cells were washed twice in
1 Dulbecco’s Phosphate-Buffered Saline, pH 7.4 (Life Technologies),
containing 0.5 mM MgCl2, 0.5 mM CaCl2 and 0.2% fatty acid-free BSA,
and then incubated in the presence or absence of 10 nM insulin at
37 C for 30 min. Uptake of 50 mM 2-deoxyglucose and 0.2 mCi 2-
deoxy-D-[3H]-glucose (PerkinElmer) per well was measured over the
ﬁnal 10 min of this incubation. Cells were washed twice in ice-cold
phloretin (80 mg/mL) in PBS and lysed in 0.03% SDS before being
analysed by scintillation counting. Protein content per well was
measured and results expressed as pmol glucose transported per
minute per mg of protein.
2.4. Glucose production assay
FAO hepatocytes in 48-well plates were treated for 24 h with mito-
chondrial inhibitors or insulin sensitising agents in GP media in the
presence or absence of 0.1 nM insulin. To measure the glucose
produced by the cells, 40 ml of media was collected from each well and
combined with 250 ml of Assay Buffer consisting of 0.12 M NaH2-
PO4$2H2O pH 7.0, 1 mg/mL phenol, 0.5 mg/mL 4-aminoantipyrine,
1.6 units/mL peroxidise and 10 units/mL glucose oxidase. This was
incubated for 25 min at 37 C after which absorbance was measured
at 490 nm. Cells were lysed in 100 ml 0.03% SDS and protein was
quantiﬁed using a BCA Protein Assay kit (Pierce). Results are
expressed as mg glucose per mg protein.pen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 1: Diverse models of cell-autonomous insulin resistance in 3T3L1 adipocytes is not associated with a common perturbation in mitochondrial function. (A) Basal and insulin-stimulated (10 nM)
2-deoxyglucose uptake; (B) Insulin signalling; (C) LDH release; (D) Oxygen consumption due to basal respiration, ATP turnover and Hþ leak; (E) Mitochondrial membrane potential (MMP); and (F)
Mitochondrial ROS production, in vehicle (Veh), glucose oxidase (G.O.; 25 mU/mL), TNFa (10 ng/mL) and chronic insulin (10 nM) treated (24 h) cells. Data presented as mean  SEM, n ¼ 3e6
biological replicates. Denotes signiﬁcantly different from; # vehicle/non-insulin-treated cells, * vehicle/insulin-treated cells; and y vehicle-treated cells (p < 0.05).
Original articleAn alternative method was used to measure glucose production in
hepatocytes co-treated with MnTBAP as the colour of MnTBAP in-
terferes with any colorimetric measurement. Cells were seeded and
treated as in the colorimetric assay and instead glucose production
was measured by a ﬂuorometric assay kit (Cayman Chemical Com-
pany) following the manufacturer’s instructions. Cells were lysed in
100 ml 0.03% SDS and protein was quantiﬁed using a BCA Protein
Assay kit (Pierce). Results are expressed as mg glucose per mg protein.
2.5. Western blot analysis
Cells in 6-well plates were treated for 24 h as described above, in the
absence or presence of insulin for the ﬁnal 15 min (3T3L1 10 nM
insulin in serum-starve media; FAO 0.1 nM insulin). Proteins were
extracted using protein lysis buffer (50 mM Tris pH7.5, 1 mM EDTA,
1 mM EGTA, 10% glycerol, 1% triton X-100, 50 mM NaF, 5 mM
Na4P2O7, 1 mM Na3VO4, 1 mM DTT, protease inhibitor cocktail) and
protein concentration quantiﬁed using a BCA Protein Assay kit (Pierce).
30 mg of protein was separated by SDS-PAGE and transferred onto
PVDF membrane using standard protocols. Membranes were blocked
for 1 h at room temperature (RT) in TBST (TBS with 0.05% Tween 20,
pH 7.4) containing 1% BSA, and incubated overnight at 4 C with the
following primary antibodies, at the dilutions indicated, in TBST: anti-
pY612 IRS1 (1:1000, Upstate), anti-IRS1 (1:1000, Upstate), anti-pS473
Akt (1:1000, Cell Signaling), anti-Akt (1:1000, Cell Signaling), anti-
pS462 AS160 (1:1000, Cell Signaling), anti-AS160 (1:1000, Up-
state), anti-pT24 FoxO1 (1:1000, Cell Signaling), anti-FoxO1 (1:1000,
Cell Signaling), anti-a-tubulin (1:1,000; SigmaeAldrich). Membranes
were washed with TBST before being exposed to the appropriate HRP
conjugated secondary antibody at a dilution of 1:10,000 in TBST for 1 h
at RT. The reaction was developed using chemiluminescence (Invi-
trogen) and visualised using the ChemiDoc XRSþ with Image Lab
software.410 MOLECULAR METABOLISM 3 (2014) 408e418  2014 The Authors. Published by Elsevier GmbH2.6. Lactate dehydrogenase cytotoxicity assay
Lactate dehydrogenase (LDH) is released from cells upon loss of
membrane integrity due to apoptosis or necrosis and can therefore be
used as a measure of cell viability. Cells in 48-well plates were treated
as described above (3T3L1 in serum-starve media). After 24 h the
cytotoxic effects of our treatments were assessed using the CytoTox
96 Non-Radioactive Cytotoxicity Assay kit (Promega) as per manu-
facturer’s instructions. Viability was expressed as LDH in the media
normalised to total LDH from the media and cell lysate.
2.7. Mitochondrial membrane potential measurement
Mitochondrial transmembrane potential was measured using the
membrane-permeable JC-1 dye (Invitrogen). Cells in black-walled 96-
well plates were treated for 24 h as described above. In the ﬁnal
10 min of treatment, cells were incubated with 10 mg/mL JC-1 dye at
37 C. After three washes with PBS, both green and red ﬂuorescence
emissions were measured using an excitation wavelength of 488 nm
and emission wavelengths of 522 and 605 nm, respectively.
2.8. Mitochondrial superoxide measurement
MitoSOX Red (Molecular Probes) was used to measure mitochon-
drial speciﬁc superoxide. Cells in black-walled 96-well plates were
treated for 24 h as described above. In the ﬁnal 30 min of treatment,
cells were incubated with 1mM MitoSOX Red at 37 C. After two
washes with PBS, ﬂuorescence was measured using an excitation
wavelength of 510 nm and an emission wavelength of 580 nm.
2.9. Statistical analysis
All values are expressed as mean  SEM. Data were analysed for
statistical signiﬁcance using Minitab 15 Statistical Software. Unpaired
t-tests were used where two individual treatments were compared.
One-way ANOVA with Tukey post-hoc test was used where more than. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
www.molecularmetabolism.com
Figure 2: Impaired mitochondrial function induces insulin resistance in 3T3L1 adipocytes. (A) Basal respiration; (B) Mitochondrial function; (C) Extracellular acidiﬁcation rate (ECAR); (D) ATP
concentration; (E) Basal and insulin-stimulated (10 nM) 2-deoxyglucose uptake; (F) Insulin action; (G) Insulin signalling; and (H) Basal and insulin-stimulated (10 nM) 2-deoxyglucose uptake in the
presence or absence of MnTBAP in vehicle, 50 nM or 100 nM oligomycin treated (24 h) 3T3L1 adipocytes. (I) Basal respiration; (J) Mitochondrial function; (K) ECAR; (L) ATP concentration; (M) Basal
and insulin-stimulated (10 nM) 2-deoxyglucose uptake; (N) Insulin action; and (G) Insulin signalling in vehicle, 1 nM or 5 nM rotenone treated (24 h) 3T3L1 adipocytes. Data presented as
mean  SEM, n ¼ 3e6 biological replicates. Denotes signiﬁcantly different from; y vehicle-treated cells, # vehicle/non-insulin-treated cells, * vehicle/insulin-treated cells (p < 0.05).two groups were compared within a single treatment, and p values
less than 0.05 were considered signiﬁcant.
3. RESULTS
3.1. Mitochondrial dysfunction is not necessary for insulin
resistance in adipocytes
In vivo studies have not been able to determine whether mitochondrial
dysfunction is necessary for insulin resistance with any certainty. To
establish whether mitochondrial dysfunction is necessary for insulin
resistance, we assessed mitochondrial function indices in diverse
cellular models of insulin resistance in 3T3L1 adipocytes. These
included glucose oxidase, TNFa and chronic insulin treatment, which
all impaired insulin-stimulated glucose uptake (Figure 1A). CellularMOLECULAR METABOLISM 3 (2014) 408e418  2014 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.cominsulin resistance in these models was not attributed to a common
defect in insulin signalling at the level of IRS1, Akt or AS160
(Figure 1B). There was a small but signiﬁcant increase in LDH release
with glucose oxidase (Figure 1C), indicating compromised cell viability.
As impaired mitochondrial respiration has been linked to the devel-
opment of insulin resistance, we measured multiple mitochondrial
respiration parameters including basal respiration, respiration due to
ATP turnover and respiration due to proton leak. Glucose oxidase
decreased respiration due to ATP turnover (Figure 1D) and increased
mitochondrial ROS production (Figure 1F). Chronic insulin increased
basal respiration, respiration for ATP turnover (Figure 1D) and
decreased MMP (Figure 1E). As TNFa had no effect on any of the
parameters measured and there was no consistent mitochondrial
perturbation across all insults, these data suggest that a commonpen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 3: Impaired mitochondrial function has no effect on insulin action in FAO hepatocytes. (A) Basal respiration; (B) Mitochondrial function; (C) Extracellular acidiﬁcation rate (ECAR); (D) ATP
concentration; (E) Basal and insulin-suppressed (0.1 nM) glucose production; (F) Insulin action; and (G) Insulin signalling in vehicle and 0.5 nM oligomycin treated (24 h) FAO hepatocytes. (H) Basal
respiration; (I) Mitochondrial function; (J) ECAR; (K) ATP concentration; (L) Basal and insulin-suppressed (0.1 nM) glucose production; (M) Insulin action; (N) Insulin signalling; and (O) Basal and insulin-
suppressed (0.1 nM) glucose production in the presence of absence of wortmannin (100 nM) in vehicle and 1 nM rotenone treated FAO hepatocytes. Data presented as mean  SEM, n ¼ 3e6
biological replicates. Denotes signiﬁcantly different from; y vehicle-treated cells, # vehicle/non-insulin-treated cells, * vehicle/insulin-treated cells, D designated difference (p < 0.05).
Original article
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Figure 4: Anti-diabetic agents rosiglitazone and phenformin induce mitochondrial dysfunction and have cell type-dependent effects on insulin action. (A) Mitochondrial function; (B) Basal and insulin-
stimulated (10 nM) 2-deoxyglucose uptake; and (C) Insulin action in vehicle and 100mM rosiglitazone treated (24 h) 3T3L1 adipocytes. (D) Mitochondrial function; (E) Basal and insulin-stimulated
(10 nM) 2-deoxyglucose uptake; and (F) Insulin action in the presence or absence of MnTBAP in vehicle and 100mM rosiglitazone treated (24 h) 3T3L1 adipocytes. (G) Mitochondrial function; (H)
Basal and insulin-suppressed (0.1 nM) glucose production; (I) Insulin action; and (J) ATP levels in FAO hepatocytes treated (24 h) with increasing doses of rosiglitazone. (K) Mitochondrial function; (L)
Basal and insulin-suppressed (0.1 nM) glucose production; (M) Insulin action; and (N) ATP levels in FAO hepatocytes treated (24 h) with increasing doses of phenformin. Data presented as
mean  SEM, n ¼ 3e6 biological replicates. Denotes signiﬁcantly different from; # vehicle/non-insulin-treated cells, * vehicle/insulin-treated cells, y vehicle-treated cells (p < 0.05). ND ¼ not
detected.defect in mitochondrial function, and mitochondrial dysfunction more
generally, is not necessary for all forms of cellular insulin resistance.
3.2. Mitochondrial dysfunction by inhibition of ATP synthase or
complex I is sufﬁcient to induce insulin resistance in adipocytes,
independent of ROS production
A number of animal models with mitochondrial impairments have
unchanged or enhanced insulin action. We sought to clarify these
ﬁndings by investigating whether physiological impairment of mito-
chondrial function was sufﬁcient to induce insulin resistance. As
reduced ADP-stimulated respiration has been observed in insulin
resistant states [3,4,13], we used the ATP synthase inhibitor oligo-
mycin to mimic aspects of this defect. In 3T3L1 adipocytes,MOLECULAR METABOLISM 3 (2014) 408e418  2014 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.com24 h treatment with 50 nM and 100 nM oligomycin reduced basal
respiration byw20% andw40%, respectively (Figure 2A), similar to
that observed in insulin resistant states [13]. Three-variable (respi-
ration, membrane potential and ROS production) surface plots were
generated to represent mitochondrial function regulated by oligomy-
cin (Figure 2B). Dose-dependent reductions in respiration due to ATP
turnover (Figure S2A), but not proton leak (Figure S2B), were asso-
ciated with increased MMP and ROS production (Figure 2B,
Figure S2C and D). At 100 nM, oligomycin increased LDH release
(Figure S2E). The extracellular acidiﬁcation rate (ECAR), a proxy
measure of glycolytic rate, was increased with both doses (Figure 2C)
and was associated with an increase in cellular ATP levels
(Figure 2D). Insulin-stimulated glucose uptake was decreased withpen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
413
Original articleboth doses of oligomycin, and at 50 nM, basal glucose uptake was
increased (Figure 2E). Insulin action, assessed as the percentage
increases in insulin-stimulated glucose uptake over basal, was ab-
lated at both oligomycin doses (Figure 2F). There was also a global
reduction in expression and phosphorylation of key components of the
insulin signalling pathway (Figure 2G). As mitochondrial ROS pro-
duction has been implicated as a causative factor in insulin resistance
[19,20] and was increased in this model, the SOD mimetic MnTBAP
was used to reduce mitochondrial ROS production (Figure S2F).
MnTBAP did not restore oligomycin-induced insulin resistance, but
did reduce insulin-stimulated glucose uptake in the absence of oli-
gomycin (Figure 2H), suggesting that increased mitochondrial ROS
production does not mediate insulin resistance in this model. This
was further supported by evidence that antimycin A, a complex III
inhibitor that increases ROS production, had no effect on glucose
uptake (Figure S2G) at concentrations that reduced respiration by
w20% and w80% respectively (data not shown). These data show
that mitochondrial dysfunction, in a model that replicates aspects of
mitochondrial dysfunction seen in insulin resistant states in vivo, is
sufﬁcient to induce insulin resistance independent of mitochondrial
ROS production.
As inhibition of complex I is thought to be the mechanism of action of
some anti-diabetic agents, we examined the effect of the complex I
inhibitor rotenone on insulin action. In 3T3L1 adipocytes, 1 nM and
5 nM rotenone reduced basal respiration by w20% and w60%
respectively (Figure 2I). Altered mitochondrial function induced by
rotenone (Figure 2J) varied from that induced by oligomycin (Figure 2B)
and did not include alterations in MMP or mitochondrial ROS pro-
duction (Figure S2H and I). However, 5 nM but not 1 nM rotenone,
signiﬁcantly reduced respiration associated with ATP turnover
(Figure S2J) and proton leak (Figure S2K). While 5 nM rotenone
increased ECAR (Figure 2K), both doses of rotenone had no effect on
ATP concentration (Figure 2L) or cell viability (Figure S2L). We next
tested the effect of rotenone on insulin action in 3T3L1 adipocytes. At
5 nM, but not 1 nM, rotenone signiﬁcantly reduced insulin-stimulated
glucose uptake (Figure 2M) and insulin action (Figure 2N). There were
no obvious impairments in insulin signalling through IRS1, Akt and
AS160 (Figure 2O). These data suggest that inhibition of complex I and
its associated mitochondrial dysfunction is sufﬁcient to induce insulin
resistance in 3T3L1 adipocytes. However, this occurred only at supra-
physiological impairment of respiration. Nonetheless, these data show
that complex I inhibition does not have insulin sensitising effects in
3T3L1 adipocytes. The divergent effects of oligomycin and rotenone on
insulin signalling and the magnitude of insulin resistance show that the
exact mechanism of mitochondrial impairment is important in pre-
dicting subsequent effects on insulin action.
3.3. Impairment of ATP synthase or complex I of the ETC has no
effect on the insulin sensitivity of FAO hepatocytes, despite
increasing ROS production
Insulin-sensitive cells can differ widely in their oxidative capacity and
metabolic functions. Therefore, to determine whether mitochondrial
dysfunction is sufﬁcient to induce insulin resistance in multiple cell
types, we investigated these effects in FAO hepatocytes. Low doses of
oligomycin reduced basal respiration (Figure 3A) and altered mito-
chondrial function (Figure 3B) in FAO hepatocytes. At 0.5 nM, which
reduced respiration by w10% (Figure 3A), oligomycin did not signif-
icantly alter respiration due to ATP turnover (Figure S3A) and proton
leak (Figure S3B), but did increased MMP (Figure S3C) and ROS
production (Figure S3D). There was no change in cell viability
(Figure S3E). There were no effects on ECAR (Figure 3C) or ATP levels414 MOLECULAR METABOLISM 3 (2014) 408e418  2014 The Authors. Published by Elsevier GmbH(Figure 3D). We tested whether oligomycin-induced mitochondrial
dysfunction was sufﬁcient to reduce insulin sensitivity in FAO hepa-
tocytes by measuring insulin suppression of glucose production
(Figure 3E). Oligomycin did not alter basal or insulin suppression of
glucose production, or insulin action (Figure 3F). No effect on the in-
sulin signalling pathway was detected (Figure 3G). These data provide
evidence that increased mitochondrial ROS production does not induce
insulin resistance in these cells. Rather a reduction in mitochondrial
ROS (Figure S3F) and alteration of the cellular redox state with MnTBAP
completely impaired glucose production (Figure S3G), suggesting a
more fundamental role for ROS signalling in the control of glucose
production in these cells.
We next assessed the effect of rotenone on respiration in FAO hepa-
tocytes (Figure 3G), which altered mitochondrial function (Figure 3H).
At 1 nM, which reduced respiration byw20%, this included decreased
respiration due to ATP turnover (Figure S3H) and proton leak
(Figure S3I) but had no effect on MMP, ROS production (Figure 3H,
Figure S3J and K) or cell viability (Figure S3E). ECAR was increased
(Figure 3I) and ATP levels were unchanged (Figure 3J). Interestingly,
rotenone reduced both basal and insulin-stimulated glucose produc-
tion (Figure 3M), but had no effect on insulin action (Figure 3N). As
rotenone increased both basal and insulin-stimulated tyrosine phos-
phorylation of IRS1 (Figure 3O), we tested whether inhibiting phos-
phatidylinositol 3-kinase (PI3K) and subsequent insulin signalling with
wortmannin, would eliminate the ability of rotenone to reduce glucose
production. Wortmannin signiﬁcantly increased basal glucose pro-
duction in vehicle-treated cells, but had no effect on the ability of in-
sulin to suppress glucose production, suggesting that the canonical
insulin signalling pathway is not essential for the suppressive effects of
insulin on glucose production in this model. In the presence of wort-
mannin, rotenone was still able to decrease both basal and insulin-
stimulated glucose production (Figure 3P), suggesting that rote-
none’s actions on glucose production are not mediated through insulin
signalling pathway sensitisation.
3.4. The anti-diabetic drugs rosiglitazone and phenformin alter
mitochondrial function and have cell type-dependent effects on
insulin action
Our data show that mitochondrial dysfunction is not a universal initi-
ating factor for insulin resistance. However, inducing mitochondrial
dysfunction is sufﬁcient to induce cell type-dependent insulin resis-
tance. As rosiglitazone and phenformin exert their effects, in part,
through inhibition of complex I and the mitochondrial pyruvate carrier,
resulting in impaired mitochondrial respiration, we examined the acute
effects of these agents on mitochondrial function and insulin sensi-
tivity. In 3T3L1 adipocytes, rosiglitazone reduced mitochondrial
respiration (Figure S4A) and mitochondrial function (Figure 4A,
Figure S4B and C), however the nature of that dysfunction, based on
multiple parameter analysis varied from that induced by oligomycin
and rotenone in these same cells (Figure 2B and J), reinforcing the
importance of measuring multiple parameters of mitochondrial func-
tion. Rosiglitazone increased ATP levels (Figure S4D) independent of
increases in ECAR (Figure S4E). Consistent with our data for other
mitochondrial inhibitors in these cells, insulin action was decreased by
rosiglitazone (Figure 4B and C), but this was driven by an increase in
basal glucose uptake (Figure 4B). Phenformin induced similar alter-
ations in mitochondrial respiration (Figure S4F) and function
(Figure 4A), in adipocytes, albeit with greater inhibitory action on
respiration associated with ATP turnover and proton leak (Figures S4G
and H). No signiﬁcant changes in ATP levels (Figure S4I) or ECAR
(Figure S4J) were detected with phenformin treatment. Although. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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phenformin increased basal glucose uptake (Figure 4E), insulin action
was also completely abrogated (Figure 4F). As phenformin increased
mitochondrial ROS production (refer ahead to Figure 5D), we used
MnTBAP to counter this increase, with no effect on insulin action
(Figure 4E and F). This shows that in this cell type, heterogeneous
forms of mitochondrial dysfunction converge to induce insulin resis-
tance, independent of increased mitochondrial ROS production. These
drugs also altered mitochondrial function in FAO hepatocytes
(Figure 4G and K, Figure S4KeO, QeU). Rosiglitazone at high doses
reduced both basal and insulin suppression of glucose production
(Figure 4H) and increased insulin action (Figure 4I). As recent evidence
links the efﬁcacy of biguanides on hepatic glucose production to
reduced ATP levels [34], we also assessed ATP concentrations.
However, rosiglitazone did not reduce ATP levels (Figure 4J), nor ECAR
(Figure S4P). Phenformin at higher doses also reduced basal and
insulin-stimulated glucose production (Figure 4L), but not insulin action
(Figure 4M), despite reduced ATP levels (Figure 4N) and no compen-
satory change in ECAR (Figure 4SV). These data show that similar to
traditional mitochondrial inhibitors, these anti-diabetic agents have cell
type-dependent effects on mitochondrial function and insulin action.
3.5. Rosiglitazone and phenformin do not impair mitochondrial
ROS production in 3T3L1 adipocytes
While the exact mechanism linking the effects of rosiglitazone and
phenformin on mitochondrial function and insulin action remain un-
clear, one proposed mechanism is that these compounds can reduce
ROS production under conditions of mitochondrial dysfunction [27],
suggesting that these drugs could have altered efﬁcacy in stressed and
healthy states. While we have not found a role for ROS production
linking mitochondrial dysfunction and insulin resistance in our models,
we nonetheless explored this possibility. We induced mitochondrial
dysfunction in 3T3L1 adipocytes with glucose oxidase, which
increased ROS production (Figure 1F), and co-treated with rosiglita-
zone or phenformin before assessing insulin action (Figure 5A).
Glucose oxidase-induced insulin resistance was worsened with
increasing doses of both rosiglitazone and phenformin (Figure 5A).Figure 5: Rosiglitazone and phenformin do not impair mitochondrial ROS production in 3T3L1 adip
glucose oxidase (Gluc. Ox.; 25 mU/mL) and increasing doses of either rosiglitazone and phenformi
potential (MMP) in 3T3L1 adipocytes treated (24 h) with glucose oxidase and rosiglitazone. (D) Mi
(MMP) in 3T3L1 adipocytes treated (24 h) with glucose oxidase and phenformin. Data presented as m
treated cells, z glucose oxidase/insulin-treated cells, ! glucose oxidase/vehicle-treated cells, - cor
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idase with rosiglitazone (Figure 5B) and phenformin (Figure 5D). This
was associated with a loss in MMP with rosiglitazone that was also
worsened with glucose oxidase (Figure 5C) and with 100 mM phen-
formin and glucose oxidase (Figure 5E). These data suggest that these
compounds do not reduce ROS production under states of mitochon-
drial dysfunction in all cell types and that these anti-diabetic drugs can
further exacerbate mitochondrial dysfunction and its associated insulin
resistance under context-speciﬁc conditions.
4. DISCUSSION
These fundamental studies on the relationship between mitochondrial
function and cell-autonomous insulin action revealed that acute,
physiological impairments in mitochondrial function are sufﬁcient, but
not necessary, to induce insulin resistance (Figure 6). Deﬁnitive con-
clusions on this issue have been elusive in human and animal studies.
This has been partly due to the difﬁcultly in inducing physiological
impairments in mitochondrial function in animal models either through
genetic or other means. In addition, interventionist human studies have
found it difﬁcult to separate mitochondrial dysfunction with other
confounding variables, such as increased fatty acid availability, which
is also associated with insulin resistance [30,31]. However the utility of
our cell-autonomous system that allows titration of mitochondrial
impairment to physiological levels and analysis of insulin action under
conditions of constant substrate availability, without the inﬂuence of
inter-tissue crosstalk, has assisted with mechanistic dissection of this
relationship. These ﬁndings support data in humans with mitochondrial
impairments due to mitochondrial DNA mutations, which can also
manifest in insulin resistance in key insulin-sensitive tissues [14e16].
Numerous animal models with impaired mitochondrial function due to
genetic or dietary modiﬁcation of components of the electron transport
chain have produced opposing conclusions on this same issue. For
example, deletion of the apoptosis initiating factor (AIF) enzyme that is
a component of complex I, leads to oxidative phosphorylation defects
and protection against insulin resistance in response to high fat feedingocytes. (A) Basal and insulin-stimulated (10 nM) glucose uptake in 3T3L1 adipocytes treated with
n; (B) Mitochondrial ROS production via mitosox ﬂuorescence; and (C) Mitochondrial membrane
tochondrial ROS production via mitosox ﬂuorescence; and (E) Mitochondrial membrane potential
ean  SEM, n ¼ 3e6 biological replicates. Denotes signiﬁcantly different from; * vehicle/insulin-
responding treatment group/no glucose oxidase treated cells (p < 0.05).
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Figure 6: Complexity linking impaired mitochondrial function to insulin action. Cell type- and impairment site-speciﬁc relationships between mitochondrial dysfunction and insulin action in adipocytes
and hepatocytes.
Original article[22]. Similar ﬁndings are observed with the ablation of cytochrome c
oxidase subunit VI peptide 2a (Cox6a2; 23) and iron-containing en-
zymes of the ETC [21]. However, data from the present study could
reconcile these ﬁndings. For example, we showed that complex I in-
hibition decreased insulin-stimulated glucose uptake in adipocytes, but
potentiated insulin suppression of glucose production in hepatocytes.
These data showing that identical insults have cell type-dependent
effects on mitochondrial function and insulin action highlights the
complexity in this relationship (Figure 6). Multi-parameter measure-
ment and representation of mitochondrial function in a multi-
dimension format in the form of surface plots was also useful in
identifying the heterogeneous nature of mitochondrial dysfunction by
common insults. Furthermore, the speciﬁc mitochondrial enzymes
impaired also determine the impact on insulin action. Indeed, oligo-
mycin and rotenone had differential effects on insulin signalling and
the magnitude of insulin resistance in 3T3L1 adipocytes, despite
similar impairments in respiration. These data suggest that animal
models with global defects in mitochondrial function could manifest
different phenotypes depending on the site of the mitochondrial
impairment and on the speciﬁc insulin-sensitive tissue that dominates
the whole body phenotype. The impact on whole body insulin action
would therefore be difﬁcult to identify and predict. The functional
signiﬁcance of these ﬁndings are that any phenotypic investigation into
the role of mitochondria in the pathogenesis of insulin resistance in
patients or disease models will likely have to establish the exact tissue
and enzyme(s) affected to understand the mechanisms involved.
Furthermore, the biological complexity in mitochondrial regulation of
insulin action identiﬁed in our studies suggests that universal and
reductionist theories describing this relationship may not be possible.
Our ﬁndings also revealed that mitochondrial ROS is not a universal
driver of insulin resistance in the cellular systems examined. This
theory on the aetiology of insulin resistance has gained momentum
following a number of recent studies showing that skeletal muscle
insulin resistance can be prevented through buffering of mitochondrial
ROS [19,20]. Furthermore, buffering total cellular ROS in a number of
adipocyte models of insulin resistance was sufﬁcient to reverse insulin
resistance [32]. However, the compartmentalisation of ROS production
and the cell type-dependent responses to ROS require further
consideration when interpreting these data, as ROS is also required for
insulin action [33]. Nonetheless, mitochondrial ROS-mediated insulin
resistance appears to be a valid mechanism in skeletal muscle. It is416 MOLECULAR METABOLISM 3 (2014) 408e418  2014 The Authors. Published by Elsevier GmbHunclear why mitochondrial ROS production was not associated with
insulin resistance in our models, however this is an area that warrants
further investigation and could involve differences in anti-oxidant ca-
pacities. Such experiments could be important in determining the utility
of anti-oxidant therapies in heterogeneous insulin resistant states. The
mechanisms that link mitochondrial dysfunction and insulin action in
adipocytes and hepatocytes are also unclear. In adipocytes, mito-
chondrial dysfunction-induced alterations in calcium handling could be
important, as insulin-stimulated GLUT4 translocation and glucose
uptake are calcium sensitive [34]. Protein signalling from the mito-
chondria under states of stress could also play a role. Notably, deletion
of apoptosis-inducing factor (AIF), a protein typically released from the
mitochondria by pro-apoptotic stimuli, protects against insulin resis-
tance despite a reduction in mitochondrial respiration [22]. This could
suggest that protein-mediated signalling from mitochondria might
impact on insulin action. In hepatocytes, a recent study has found that
reduced cellular energy status can impede glucagon signalling, which
opposes insulin signalling in the control of glucogeogenesis [35].
Increased AMP might also allosterically inhibit gluconeogenic enzymes
directly to reduce gluconeogenic ﬂux [36]. However, we found no
association between reduced ATP, or any involvement for the canonical
insulin signalling pathway in our mitochondrial dysfunction models that
reduced insulin suppression of glucose production. The mechanisms
by which mitochondrial dysfunction impacts on insulin action in he-
patocytes remain to be determined.
We also observed that the anti-diabetic agents phenformin and rosi-
glitazone showed cell type-dependent impairments in mitochondrial
function and insulin action. This included enhanced suppression of
glucose production and enhanced insulin action in hepatocytes, but
also included induction of insulin resistance in adipocytes. The acute
effects of these drugs in adipocytes might be offset by longer term
remodelling of adipocyte metabolism, particularly in the case of rosi-
glitazone, which enhances the expression of PPAR dependent genes to
increase glucose disposal and lipogenesis, thereby reducing hyper-
glycemia in vivo [37]. Indeed, the reduced insulin action we observed
in rosiglitazone treated adipocytes was primarily due to an increase in
basal glucose uptake, rather than reduced insulin-stimulated glucose
uptake. Nonetheless, both anti-diabetic drugs altered mitochondrial
function in adipocytes, which could have longer term implications in
patients treated with these drugs for extended periods. Indeed, these
ﬁndings could explain inconsistencies in efﬁcacy associated with these. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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drugs and their reduced efﬁcacy over time. The ﬁnding that both drugs
exacerbated insulin resistance in the context of existing mitochondrial
dysfunction also highlights that personalised medicine approaches that
identify any mitochondrial defects could be used to develop improved
treatment strategies for patients.
In conclusion, our ﬁndings show that acute, physiological impairments
in mitochondrial function are sufﬁcient, but not necessary, for the
development of cell type-dependent insulin resistance and this is in-
dependent of mitochondrial ROS production. The translational impli-
cations from these ﬁndings are that therapies for insulin resistance that
involve modulation of mitochondrial function should be tissue speciﬁc
and their mechanism of action on mitochondria well characterised to
ensure optimal therapeutic outcomes. The complexity in the relation-
ship between mitochondrial function and insulin action revealed by
these studies provides insights into opposing conclusions on this issue
and questions reductionist theories that attempt to describe this
relationship.
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